Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.35
$7.29
$3.27
▼
$7.45
$2.73B1.5413.29 million shsN/A
CorMedix Inc stock logo
CRMD
CorMedix
$4.82
+3.4%
$7.11
$4.65
▼
$13.02
$377.25M1.481.98 million shs3.20 million shs
LendingTree, Inc. stock logo
TREE
LendingTree
$35.22
-1.5%
$27.82
$23.50
▼
$68.93
$495.90M1.99409,727 shs317,329 shs
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$13.29
-2.6%
$13.95
$9.82
▼
$20.22
$1.94B1.151.70 million shs1.64 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
0.00%0.00%0.00%+0.82%+83.75%
CorMedix Inc stock logo
CRMD
CorMedix
+3.43%-11.88%-33.61%-41.00%-57.12%
LendingTree, Inc. stock logo
TREE
LendingTree
-1.51%-3.48%+38.72%+12.70%-28.30%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-2.64%-13.19%+11.87%-29.46%+16.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.35
$7.29
$3.27
▼
$7.45
$2.73B1.5413.29 million shsN/A
CorMedix Inc stock logo
CRMD
CorMedix
$4.82
+3.4%
$7.11
$4.65
▼
$13.02
$377.25M1.481.98 million shs3.20 million shs
LendingTree, Inc. stock logo
TREE
LendingTree
$35.22
-1.5%
$27.82
$23.50
▼
$68.93
$495.90M1.99409,727 shs317,329 shs
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$13.29
-2.6%
$13.95
$9.82
▼
$20.22
$1.94B1.151.70 million shs1.64 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
0.00%0.00%0.00%+0.82%+83.75%
CorMedix Inc stock logo
CRMD
CorMedix
+3.43%-11.88%-33.61%-41.00%-57.12%
LendingTree, Inc. stock logo
TREE
LendingTree
-1.51%-3.48%+38.72%+12.70%-28.30%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-2.64%-13.19%+11.87%-29.46%+16.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
2.07
Hold$10.5643.62% Upside
CorMedix Inc stock logo
CRMD
CorMedix
2.80
Moderate Buy$15.22215.81% Upside
LendingTree, Inc. stock logo
TREE
LendingTree
2.86
Moderate Buy$53.6052.19% Upside
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
2.92
Moderate Buy$27.08103.79% Upside

Current Analyst Ratings Breakdown

Latest ATAI, TREE, CRMD, and TRVI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
CorMedix Inc stock logo
CRMD
CorMedix
Reiterated RatingOutperform$15.00 ➝ $13.00
11/12/2026
LendingTree, Inc. stock logo
TREE
LendingTree
Initiated CoverageStrong-Buy
11/10/2026
CorMedix Inc stock logo
CRMD
CorMedix
DowngradeHold (C+) ➝ Hold (C)
11/10/2026
CorMedix Inc stock logo
CRMD
CorMedix
Set Price Target$19.00
11/10/2026
CorMedix Inc stock logo
CRMD
CorMedix
Reiterated RatingMarket Outperform
11/10/2026
CorMedix Inc stock logo
CRMD
CorMedix
Boost Price TargetOutperform$14.00 ➝ $15.00
11/10/2026
CorMedix Inc stock logo
CRMD
CorMedix
Boost Price TargetBuy$12.00 ➝ $14.00
11/9/2026
LendingTree, Inc. stock logo
TREE
LendingTree
DowngradeHold (C) ➝ Hold (C-)
11/4/2026
LendingTree, Inc. stock logo
TREE
LendingTree
Lower Price TargetOverweight$48.00 ➝ $40.00
11/4/2026
LendingTree, Inc. stock logo
TREE
LendingTree
Lower Price TargetBuy$70.00 ➝ $65.00
11/2/2026
CorMedix Inc stock logo
CRMD
CorMedix
Lower Price TargetBuy$15.00 ➝ $12.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$4.09M666.46N/AN/A$0.69 per share10.65
CorMedix Inc stock logo
CRMD
CorMedix
$311.71M1.21$2.03 per share2.37$5.14 per share0.94
LendingTree, Inc. stock logo
TREE
LendingTree
$1.12B0.44$3.52 per share10.01$18.03 per share1.95
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/A$2.12 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-$660.05M-$2.18N/AN/AN/A-14,938.36%-88.30%-58.88%N/A
CorMedix Inc stock logo
CRMD
CorMedix
$163.05M$0.693.7532.130.9015.49%27.12%13.88%N/A
LendingTree, Inc. stock logo
TREE
LendingTree
$151.31M$7.0210.706.95N/A7.60%15.92%5.40%N/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$42.76M-$0.39N/AN/AN/AN/A-24.81%-23.96%N/A

Latest ATAI, TREE, CRMD, and TRVI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
CorMedix Inc stock logo
CRMD
CorMedix
-$0.12-$0.19-$0.07-$0.19$51.76 million$54.52 million
11/9/2026Q3 2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$0.1317-$0.13+$0.0017-$0.13N/AN/A
11/3/2026Q3 2026
LendingTree, Inc. stock logo
TREE
LendingTree
$1.26-$5.15-$6.41-$5.15$329.72 million$343.59 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/AN/AN/A
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
LendingTree, Inc. stock logo
TREE
LendingTree
N/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/A
CorMedix Inc stock logo
CRMD
CorMedix
0.31
2.56
2.36
LendingTree, Inc. stock logo
TREE
LendingTree
1.29
1.57
1.85
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/A
38.86
37.28

Institutional Ownership

CompanyInstitutional Ownership
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
28.41%
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
LendingTree, Inc. stock logo
TREE
LendingTree
68.26%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
95.76%

Insider Ownership

CompanyInsider Ownership
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
19.80%
CorMedix Inc stock logo
CRMD
CorMedix
3.50%
LendingTree, Inc. stock logo
TREE
LendingTree
4.00%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
15.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
80370.86 million297.43 millionOptionable
CorMedix Inc stock logo
CRMD
CorMedix
19177.94 million76.75 millionOptionable
LendingTree, Inc. stock logo
TREE
LendingTree
92614.04 million13.48 millionOptionable
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
34142.56 million120.62 millionOptionable

Recent News About These Companies

FY2026 Earnings Estimate for TRVI Issued By HC Wainwright
Trevi Therapeutics Q3 Loss Widens
Trevi Therapeutics (TRVI) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atai Beckley stock logo

Atai Beckley NASDAQ:ATAI

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

CorMedix stock logo

CorMedix NASDAQ:CRMD

$4.82 +0.16 (+3.43%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$4.86 +0.04 (+0.93%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

LendingTree stock logo

LendingTree NASDAQ:TREE

$35.22 -0.54 (-1.51%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$35.06 -0.16 (-0.44%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LendingTree, Inc., through its subsidiary, operates online consumer platform in the United States. It operates through three segments: Home, Consumer, and Insurance. The Home segment offers purchase mortgage, refinance mortgage, and home equity loans and lines of credit; and real estate brokerage services. The Consumer segment provides credit cards; personal, small business, student, and auto loans; deposit accounts; and other credit products, such as debt settlement services. The Insurance segment includes information, tools, and access to insurance quote products, including home, automobile, and health and Medicare through which consumers are matched with insurance lead aggregators to obtain insurance offers and policies. In addition, the company offers QuoteWizard, a marketplace for insurance comparison; ValuePenguin, a personal finance website that offers consumers objective analysis on various financial topics from insurance to credit cards; and Stash, a consumer investing and banking platform that offers a suite of personal investment accounts, traditional and Roth IRAs, custodial investment accounts, and banking services, including checking accounts and debit cards with a Stock-Back rewards program. The company was formerly known as Tree.com, Inc. and changed its name to LendingTree, Inc. in January 2015. LendingTree, Inc. was incorporated in 1996 and is based in Charlotte, North Carolina.

Trevi Therapeutics stock logo

Trevi Therapeutics NASDAQ:TRVI

$13.29 -0.36 (-2.64%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$13.29 0.00 (0.00%)
As of 11/16/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.